Current Report Filing (8-k)
November 07 2017 - 4:32PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 7, 2017
Regulus Therapeutics Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-35670
|
|
26-4738379
|
(State
of incorporation)
|
|
(Commission
File No.)
|
|
(IRS Employer
Identification No.)
|
|
|
10614 Science Center Drive
San Diego, CA
|
|
92121
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code:
(858) 202-6300
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934 (§
240.12b-2
of this
chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 2.02
|
Results of Operations and Financial Condition.
|
On November 7, 2017, we issued a press release
announcing our financial results for the third quarter ended September 30, 2017. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 2.02 and the attached Exhibit 99.1 are being furnished and shall not
be deemed filed for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02 and the attached exhibit shall not be
incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Regulus Therapeutics Inc.
|
|
|
|
|
Date: November 7, 2017
|
|
|
|
By:
|
|
/s/ Joseph P. Hagan
|
|
|
|
|
|
|
Joseph P. Hagan
|
|
|
|
|
|
|
President and Chief Executive Officer
|
Regulus Therapeutics (NASDAQ:RGLS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Regulus Therapeutics (NASDAQ:RGLS)
Historical Stock Chart
From Sep 2023 to Sep 2024